DeCure for Thrombophilia due to activated protein C resistance
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for thrombophilia due to activated protein C resistance — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleThrombophilia due to activated protein C resistance maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for thrombophilia due to activated protein c resistance is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
coagulation factor V (F5) — F5 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8TN9 · 3.05 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
In a 1998 study of five patients with dural sinus thrombosis, four tested positive for activated protein C resistance. Among those four, three had haemorrhagic venous infarction. The authors note that a positive finding can help explain the cause of thrombosis in affected individuals and may identify families at risk, but the study population was small and no treatment was tested.
A 1995 review defines thrombophilia broadly as a disturbance in the balance between pro- and anti-coagulation that favours inappropriate thrombosis, often diagnosed in patients under 45 with recurrent thromboembolism or a positive family history. It describes activated protein C resistance as a newly described phenomenon within the natural anticoagulant system, but provides no trial data on any drug intervention.
Two 1995 journal articles on activated protein C resistance and inherited thrombosis are referenced but their abstracts are not provided; no results, sample sizes, or treatment outcomes can be extracted from them. A 2018 case report discusses oral rehabilitation in patients with thrombophilia due to protein C deficiency, noting that anticoagulant therapy affects haemostasis, but it offers no drug efficacy data and does not address activated protein C resistance specifically.
No controlled trial has tested any drug for thrombophilia specifically due to activated protein C resistance. What is missing is a prospective trial that stratifies patients by the presence of factor V Leiden mutation, measures thrombotic event rates with and without anticoagulation, and includes sufficient follow-up to assess bleeding risk. Funding for such a trial and a standardised definition of clinically meaningful endpoints remain absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Roentgenology · 1998 · 17 citations
Dural sinus thrombosis associated with activated protein C resistance: MR imaging findings and proband identification.
AbstractOBJECTIVE: The purpose of this study was to report the association of dural sinus thrombosis with a hypercoagulable state associated with activated protein C resistance. CONCLUSION: In our small study population, hemorrhagic venous infarction was common (three of four patients) among patients with dural sinus thrombosis and activated protein C resistance. Four of five patients with dural sinus thrombosis had positive tests for activated protein C resistance. This finding, in conjunction with data from other studies, suggests that patients with dural sinus thrombosis may need to be studied for the presence of activated protein C resistance. A positive finding for activated protein C resistance can be important not only in helping to explain the cause of thrombosis in affected individuals but also in identifying families at risk for thrombosis.
American Journal of Clinical Pathology · 1995 · 10 citations
Activated Protein C Resistance and Inherited Thrombosis
AbstractJournal Article Activated Protein C Resistance and Inherited Thrombosis Get access George M. Rodgers, MD, PhD George M. Rodgers, MD, PhD Departments of Pathology and Medicine Veterans Affairs and University of Utah Medical Centers Salt Lake City, Utah and Associated Regional and University Pathologists Search for other works by this author on: Oxford Academic Google Scholar American Journal of Clinical Pathology, Volume 103, Issue 3, 1 March 1995, Pages 261–262, https://doi.org/10.1093/ajcp/103.3.261 Published: 01 March 1995
American Journal of Clinical Pathology · 1995 · 2 citations
Activated Protein C Resistance and Inherited Thrombosis
AbstractJournal Article Activated Protein C Resistance and Inherited Thrombosis Get access Mary Cushman, MD, Mary Cushman, MD Laboratory for Clinical Biochemistry Research University of Vermont Burlington, Vermont Search for other works by this author on: Oxford Academic Google Scholar Edwin G. Bovill, MD, Edwin G. Bovill, MD Laboratory for Clinical Biochemistry Research University of Vermont Burlington, Vermont Search for other works by this author on: Oxford Academic Google Scholar Russell P. Tracey, PhD Russell P. Tracey, PhD Laboratory for Clinical Biochemistry Research University of Vermont Burlington, Vermont Search for other works by this author on: Oxford Academic Google Scholar American Journal of Clinical Pathology, Volume 104, Issue 3, 1 September 1995, Page 357, https://doi.org/10.1093/ajcp/104.3.357 Published: 01 September 1995
Journal of The Royal Naval Medical Service · 1995 · 0 citations
Thrombophilia: Some recent advances in understanding
AbstractThrombophilia is a term with many definitions although the majority include criteria such as thrombosis under the age of 45; recurrent thromboembolism and a positive family history. It reflects a disturbance in the normal delicate balance between pro- and anti-coagulation such as to favour inappropriate thrombosis. This review concentrates on the newly described phenomenon of activated protein C resistance while reviewing the natural anticoagulant system. It will also briefly examine the indications for 'thrombophilia' screening and the implications for individuals found to have an abnormality of their natural anticoagulants.
International Journal of Medical and Surgical Sciences · 2018 · 0 citations · open access
Therapeutic Approach in Oral Rehabilitation of Patients Diagnosed with Thrombophilia, Protein C Deficiency
AbstractThrombophilia is defined as any alteration, either congenital or acquired, which promotes and/or facilitates the presentation of a thrombotic phenomenon. Drug treatment of this condition is to prevent (prophylaxis) other thrombotic event by anticoagulant therapy and hemostasis is affected, taking this great implication in the therapeutic approach in oral rehabilitation, leaning realize treatments with prosthetic structures on implants, teeth or tissue-borne. The aim of this case report is to present therapeutic alternatives in patients diagnosed with thrombophilia with protein C deficiency.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
